Navigation Links
AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
Date:9/25/2008

QUEBEC CITY, Sept. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its President and CEO, Jrgen Engel, PhD, will present a company overview at BioContact Quebec on Thursday, October 2, 2008, at 2:00 pm (eastern time) in the Salle Frontenac of the Fairmont Le Chateau Frontenac hotel in Quebec City, Canada.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
4. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
5. AEterna Zentaris Sells Quebec City Building for $7.1 million
6. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
7. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
8. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
9. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
10. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
11. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... King of Prussia, PA (PRWEB) , ... June ... ... bringing industry knowledge and superior results to clients throughout the biopharma and life ... the rapid changes the industry is seeing. Tunnell’s Kip Wolf will be speaking ...
(Date:6/20/2017)... ... June 20, 2017 , ... CTNext , ... directors has formed a Higher Education Entrepreneurship Advisory Committee to implement the recommendations ... and other high-ranking representatives from 35 higher education institutions across the state over ...
(Date:6/20/2017)... ... June 20, 2017 , ... National executive search firm, ... extensive assay development and biomarker expertise, as VP of Scientific Affairs at Cambridge ... in bio-analytical assay development and sample testing services. The organization acts as a ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., ... today that it is launching two new additions of its award-winning cloud-based platform ... capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):